1 / 9

June 04

June 04. CFA - A Collection of Sample Slides. Index for Merck’s CFA (full coverage) Merck - Involvement in Key Therapeutic Sectors Merck - Therapeutic Portfolio - Historical Trends Merck Cardiovascular Franchise - Gap Analysis Merck Cardiovascular Franchise - Portfolio Maturity (2003 sales)

brenna
Download Presentation

June 04

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. June 04 CFA - A Collection of Sample Slides • Index for Merck’s CFA (full coverage) • Merck - Involvement in Key Therapeutic Sectors • Merck - Therapeutic Portfolio - Historical Trends • Merck Cardiovascular Franchise - Gap Analysis • Merck Cardiovascular Franchise - Portfolio Maturity (2003 sales) • Merck Presence in Metabolism Sector (2003) • Merck - Therapeutic Breakdown • Merck - Therapeutic Portfolio - Key Indices (2003-08)

  2. Index for Merck’s CFA Therapeutic Franchise Sectors Franchise Development & Future Outlook Corporate Assessment • Cardiovasculars • Anti-infectives • Metabolism • Musculoskeletal & Pain • Respiratory • Genito-urinary • Vaccines • Ophthalmology • Peripheral areas • CNS • Emerging areas • Oncology • Strategic Goals & Growth • projections • Business operations • Historical • 2003 • Recent Corporate initiatives • Ranking by sales • Key therapeutic sectors • Therapeutic portfolio • Historical • 2003 • Key therapeutic • franchises • Therapeutic breakdown • Therapeutic portfolio - Key • indices • Franchise market shares • Outlook for Merck’s Pharma • Business WoodMac/CFA/Merck & Co/Index/Jun 04/Page 2

  3. Merck - Involvement in Key Therapeutic Sectors Respiratory Market Leading Franchise Emerging Franchise Areas Secondary Franchise Areas No Presence in Area Ophthalmology (& Sensory Organs) Dermatology Cardiovasculars Genito-urinary CNS GI Musculoskeletal & Pain Anti-infectives Oncology (& support therapies) Metabolism Vaccines Transplant WoodMac/CFA/Merck & Co/Corporate Assessment/Jun 04/Page 9

  4. Merck - Therapeutic Portfolio - Historical Trends…. 1998 - $15.3bn 1995 - $9.9bn Others 3% Cardiovasculars Vaccines 5% 63% Ophthalmology 6% Genito-urinary 4% GI 10% Anti-Infectives 9% Cardiovasculars $8.9bn Anti-infectives $1.4bn Vaccines $0.9bn Metabolism $0.8bn Ophthalmology $0.6bn Genito-urinary $0.4bn Respiratory $0.2bn Others $2.1bn Cardiovasculars $6.2bn Gastro-intestinal $1.0bn Anti-infectives $0.9bn Ophthalmology $0.6bn Vaccines $0.5bn Genito-urinary $0.4bn Others $0.3bn WoodMac/CFA/Merck & Co/Corporate Assessment/Jun 04/Page 10

  5. Merck Cardiovascular Franchise - Gap Analysis WoodMac/CFA/Merck & Co/Cardiovasculars/Jun 04/Page 19

  6. Merck Cardiovascular Franchise - Portfolio Maturity (2003 sales) Prinivil ($116m) Zetia ($235m) Vasotec ($0.8bn) High Zocor ($5bn) Maturity Cozaar ($2.5bn) Demand Decline Growth Low Vytorin Aggrastat ($96m) Launch Time WoodMac/CFA/Merck & Co/Cardiovasculars/Jun 04/Page 21

  7. Merck Presence in Metabolism Sector (2003) Metabolism Market 2003 ($36.6bn) WoodMac/CFA/Merck & Co/Metabolism/Jun 04/Page 39

  8. Merck - Therapeutic Breakdown 2003 - $23.1bn 2008 - $28.7bn Cardiovasculars * $9.2bn Metabolism $5.1bn Respiratory $4.2bn Musculoskeletal & Pain $2.8bn Anti-infectives $1.9bn Vaccines** $1.7bn Ophthalmology $0.8bn CNS $0.5bn Oncology $0.4bn Genito-urinary $0.2bn Other $1.9bn Cardiovasculars * $9.2bn Metabolism $2.7bn Musculoskeletal & Pain $2.6bn Respiratory $2.0bn Vaccines** $1.4bn Anti-infectives $1.3bn Ophthalmology $0.7bn Genito-urinary $0.6bn CNS $0.3bn Other $2.2bn Forecast Compound Growth Rate 2003-08 = 4.5% * includes 50% of Zetia and Vytorin sales through the Merck Schering-Plough alliance ** includes 50%of sales through the AP-MSD European vaccine joint venture WoodMac/CFA/Merck & Co/Future Outlook/Jun 04/Page 115

  9. Merck - Therapeutic Portfolio - Key Indices (2003-08) N.B. Data sourced from Wood Mackenzie’s PharmaQuant Plus - April 2004 The indices in this table relate to Merck’s key global brands only WoodMac/CFA/Merck & Co/Future Outlook/Jun 04/Page 116

More Related